2024
Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factors
2022
Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery
Bakkila BF, Kerekes D, Nunez-Smith M, Billingsley KG, Ahuja N, Wang K, Oladele C, Johnson CH, Khan SA. Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery. JAMA Network Open 2022, 5: e225664. PMID: 35377425, PMCID: PMC8980937, DOI: 10.1001/jamanetworkopen.2022.5664.Peer-Reviewed Original ResearchConceptsGastrointestinal tract cancerNegative resection marginsTract cancerNegative surgical marginsBlack patientsAdequate lymphadenectomyWhite patientsQuality of careRacial disparitiesSurgical resectionResection marginsSurgical marginsSurgical careNational Cancer DatabaseRetrospective cohort studySite of cancerLonger median survivalHealth careStandard of careCommon age rangeSignificant racial disparitiesAdjuvant chemotherapyBiliary resectionAdjuvant therapyAdult patients
2015
Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure and Perineal Flap Reconstruction
Althumairi AA, Canner JK, Ahuja N, Sacks JM, Safar B, Efron JE. Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure and Perineal Flap Reconstruction. World Journal Of Surgery 2015, 40: 225-230. PMID: 26336877, DOI: 10.1007/s00268-015-3224-0.Peer-Reviewed Original ResearchConceptsFlap reconstruction groupAdjuvant chemotherapyFlap reconstructionPrimary closureAbdominoperineal resectionWound complicationsRectal adenocarcinomaReconstruction groupWound healingPerineal flap reconstructionPerineal wound complicationsPrimary closure groupPerineal wound closureLength of healingRetrospective reviewClosure groupChemotherapyPatientsPerineal defectsWound closureHealingResectionComplicationsAdenocarcinomaLength of time
2014
The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma
Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, Rezaee N, Herman J, Zheng L, Laheru D, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL, Weiss MJ. The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. Annals Of Surgical Oncology 2014, 21: 2873-2881. PMID: 24770680, PMCID: PMC4454347, DOI: 10.1245/s10434-014-3722-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsPancreaticoduodenectomyPostoperative ComplicationsPrognosisRadiotherapy, AdjuvantRetrospective StudiesSurvival RateConceptsAdjuvant therapyPostoperative complicationsMedian survivalMultivariate analysisClavien-Dindo complication gradeTherapy warrants further investigationMultimodality adjuvant therapyOverall complication rateMethodsA retrospective reviewGrade of complicationsLonger median survivalLength of stayWarrants further investigationAdjuvant chemotherapyMedian TTANeoadjuvant approachComplication gradeComplication rateSevere complicationsRetrospective reviewClinicopathological dataResultsA totalPancreaticoduodenectomyRadiation therapyComplicationsPrognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Annals Of Oncology 2014, 25: 2314-2327. PMID: 24718889, PMCID: PMC4239805, DOI: 10.1093/annonc/mdu149.Peer-Reviewed Original ResearchConceptsDisease-free survivalCpG island methylator phenotypeColorectal cancer patientsCRC patientsOverall survivalHazard ratioPredictive factorsPrognostic valueCancer patientsPredictive valuePatient disease-free survivalShorter disease-free survivalCancer-specific mortalityAdditional survival benefitMethylator phenotypeShorter overall survivalMicrosatellite instability statusAdjuvant chemotherapyDFS benefitSurvival benefitWorse prognosisCRC prognosisPooled analysisSubgroup analysisNineteen studiesFunctional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV. Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer. Clinical Cancer Research 2014, 20: 1856-1864. PMID: 24486589, PMCID: PMC4019442, DOI: 10.1158/1078-0432.ccr-13-2109.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerThree-gene panelLung cancerIndependent cohortPrimary NSCLC samplesCell lung cancerNSCLC cell linesNovel diagnostic biomarkersAdjuvant chemotherapyMolecular diagnostic testsCancer Genome AtlasCancer mortalityCancer-specific methylationSurgical specimensNSCLC samplesMolecular stagingEarly diagnosisDiagnostic biomarkersNormal tissuesDiagnostic testsCohortCancerGenome AtlasMethylation biomarkersCell lines
2011
Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer
Qiu H, Herman JM, Ahuja N, DeWeese TL, Song DY. Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer. Practical Radiation Oncology 2011, 2: e77-e84. PMID: 24674189, DOI: 10.1016/j.prro.2011.11.001.Peer-Reviewed Original ResearchSynchronous prostateRectal cancerAdjuvant chemotherapyPelvic chemoradiationProstate brachytherapyGrade 3 gastrointestinal toxicityHigh-risk prostate cancerCarcinoembryonic antigen levelLow anterior resectionTreatment-related toxicityEvidence of relapseInterstitial prostate brachytherapyProstate interstitial brachytherapyInternal Review BoardAnterior resectionBony metastasesGastrointestinal toxicityLoop ileostomyNeoadjuvant chemoradiationRetrospective reviewAntigen levelsMonths postdiagnosisPhysical examinationProstate cancerInterstitial brachytherapy